Swedish Orphan Biovitrum
278.2 SEK -2.66%3 investors are following this company
Swedish Orphan Biovitrum, also known as Sobi, is an international pharmaceutical company. The company is focused on the research and development of treatments and belonging services for patients with rare diseases. The products are mainly focused on the treatment of inflammatory and genetic diseases. Sobi also markets specialized wound patches under various brands. The head office is located in Stockholm.
Revenue
22.12B
EBIT %
18.38 %
P/E
37.24
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
SOBI
Daily low / high price
277.8 / 285.8
SEK
Market cap
98.58B SEK
Turnover
72.54M SEK
Volume
260K
Financial calendar
Interim report
2024-07-16
Interim report
2024-10-24
Annual report
2025-02-05
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Investor | 34.7 % | 34.7 % |
Morgan Stanley Smith Barney | 9.9 % | 9.9 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Swedish Orphan Biovitrum AB: Sobi initiates rolling biologics license application to FDA for SEL-212 for the potential treatment of chronic refractory gout
Swedish Orphan Biovitrum AB: EU-kommissionen beviljar Sobi® marknadsgodkännande för ALTUVOCT™ för behandling av hemofili A
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools